Pricing Log in Create free account

Nurix Therapeutics, Inc. (NRIX) vs Ultragenyx Pharmaceutical Inc. (RARE)

Nurix Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. are both Biotechnology companies. Nurix Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. are of similar size ($1.7B and $1.7B). Ultragenyx Pharmaceutical Inc. has negative trailing earnings, so its P/E is not meaningful; Nurix Therapeutics, Inc. trades at 6.2×. Nurix Therapeutics, Inc. grew revenue faster over the last twelve months: 738.8% against 15.8%. Nurix Therapeutics, Inc. has the higher net margin (42.0% vs −71.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Nurix Therapeutics, Inc. leads on 11 and Ultragenyx Pharmaceutical Inc. on 4.

Valuation

Metric NRIX RARE Biotechnology median
P/E 6.18 n/m 11.36
P/S 2.47 2.25 9.12
P/B 1.79 n/m 2.14
Price to free cash flow 4.68 n/m 26.34
EV/EBITDA 2.31 n/m 0.62
EV/Sales 0.97 1.89 8.56
Earnings yield 16.18% (32.17%) (34.18%)
Free cash flow yield 21.37% (27.15%) (23.62%)

Profitability

Metric NRIX RARE Biotechnology median
Gross margin 100.00% 82.88% 67.24%
Operating margin 41.27% (63.98%) 0.00%
Net margin 42.01% (71.72%) 0.00%
Free cash flow margin 52.68% (61.20%) 0.00%
Return on equity 43.99% 285.46% (50.28%)
Return on assets 34.33% (44.05%) (45.89%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NRIX RARE Biotechnology median
Revenue growth (TTM) 738.76% 15.78% 6.96%
EPS growth (last fiscal year) (5.90%) 7.31% 29.86%
Revenue growth, 5-year CAGR 36.35% 19.95% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NRIX RARE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 8.44 1.40 4.72
Net debt to EBITDA 2.14 1.35 1.01

Dividend

Metric NRIX RARE Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric NRIX RARE Biotechnology median
Market cap 1.70b 1.66b 167.45m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack